Silk Road Medical has announced the launch of its tapered Enroute transcarotid stent system to hospitals in the USA, expanding upon the company’s prior Enroute transcarotid stent system and offering additional configurations to better tailor the transcarotid artery revascularisation (TCAR) procedure to patient anatomy.
“The new tapered stent is a welcome addition to my TCAR toolkit, further differentiating the company’s core product offering,” said Joseph Lombardi (Cooper University Health Care, Camden, USA). “The Enroute stent has always provided comprehensive lesion coverage and durable procedural outcomes, but I now have more options to customise treatment to each patient’s anatomy.”
“As pioneers in stroke prevention, our product development efforts are focused on extending our lead in the minimally invasive treatment of carotid artery disease,” said Chas McKhann, chief executive officer of Silk Road. “New tapered configurations for our Enroute transcarotid stent system build upon the robust portfolio of Silk Road’s carotid solutions. We are pleased to bring this portfolio expansion to market as part of our commitment to offering a diverse toolkit for physicians, allowing them to address individual patient anatomy.”
TCAR is a minimally invasive surgical procedure designed to provide best-in-class stroke protection while minimising adverse events in patients requiring treatment for carotid artery stenosis.
The Enroute transcarotid stent system is the only commercially available transcarotid stent system indicated for patients at high risk and standard risk for adverse events from carotid endarterectomy (CEA), as per a Silk Road press release. It features an optimised cell design balancing lesion coverage and anatomical conformability for long-term plaque stabilisation—and was purpose-built for TCAR, with a short delivery system for ergonomic and precise stent delivery.
